Posts tagged liver
Leerink ups Dova to OP, price target to $32

Leerink upgraded for Dova Pharmaceuticals (NASDAQ:DOVA) to “outperform” from “market perform” and raised its price target to $32 from $24 after competitor, Shionogi, announced results from a Phase 3 trial. Shares of Dova closed at $22.45 on Sept. 25.

Read More
Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22.

Read More
HCW upgrades CymaBay to buy

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on Jan. 27.

Read More
Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday.

“We believe the current valuation, close to the mid-point of the IPO range of $16-$18, represents an attractive entry point to own one of the most exciting technology platforms biotech has to offer,” writes analyst Michael Schmidt.

Read More
HCW downgrades CymaBay to neutral

H.C. Wainwright has downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “neutral” from “buy” with a price target of $2.25. The stock closed at $2.44 on Tuesday.

Yesterday, CymaBay discontinued its exploratory Phase 2 study of MBX-8025 for the treatment of primary biliary cholangitis (PBC) because the study already met its objective of establishing proof-of-concept by showing marked improvements in markers of cholestasis.

Read More
HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday.

Tobira is focused on the development of a sole drug candidate, cenicriviroc (CVC), as a treatment for non-alcoholic steatohepatitis (NASH). NASH is a disease of the liver that can lead to fibrosis, cirrhosis, and ultimately, transplant or hepatocellular carcinoma.

Read More
HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.

Galmed is focused on the development of a sole drug candidate, aramchol, as a potentially disease-modifying treatment for nonalcoholic steatohepatitis (NASH).

Read More